Cerebrolysin (60mg)

Research Overview

A parenteral neuropeptide preparation produced by controlled enzymatic breakdown of purified porcine brain proteins. Contains active low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors, with demonstrated neuroprotective and neurotrophic activity across stroke, TBI, and dementia models.

Origin: Enzymatically standardized hydrolysate of purified porcine brain proteins; clinically used in Europe and Asia

Mechanism of Action

• Neurotrophic factor-like activity (BDNF, GDNF, NGF mimetic)

• Reduction of excitotoxicity and free-radical damage

• Inhibition of calpain-mediated apoptosis

• Enhanced neurogenesis in dentate gyrus

• Modulation of microglial inflammation

Primary Research Areas

• Ischemic stroke recovery

• Traumatic brain injury

• Vascular dementia

• Alzheimer's disease research

• Neurodevelopmental models

Key Published Findings

• CASTA trial: significant functional improvement after acute ischemic stroke (Heiss et al., 2012)

• Dose-dependent cognitive improvement in mild-to-moderate Alzheimer's (Álvarez et al., Neurobiol Aging 2006)

• Reduced infarct volume and apoptosis in rodent MCAO models

Research Protocol

Commonly studied routes: Intravenous, Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.

Storage

Store below 25°C. Protect from light. Do not freeze

Important Notice

Cerebrolysin (60mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.